Phase 3 Trial – Benlysta

Phase 3 Trial Finds Benlysta Significantly Improves Kidney Response in People with Lupus Nephritis UPDATE 16/09/2020 In new results on the international phase 3 clinical trial (BLISS-LN) of the drug Benlysta (belimumab), researchers found that Benlysta reduced the risk of worsening kidney function during the study by almost 50%, compared with standard therapy alone. The…

RUNWEST 2020

Hi there! I’m making a difference and running 12km in October for a cause that’s close to my heart. My girlfriend has recently started treatment for Lupus and has battled with several of its symptoms for the past 7 years. With this, we no longer need to keep searching for answers and can start treating…

Update – Access to Hydroxychloroquine

Access to Hydroxychloroquine for People with Lupus The Lupus Association of NSW is aware of the potential use of hydroxychloroquine and chloroquine for the treatment of coronavirus (COVID-19). This means that some people with Lupus who use hydroxychloroquine to manage their condition are having difficulty accessing this medication. Hydroxychloroquine, a medication taken by approximately 90% of…

COVID-19 & Access to Hydroxychloroquine

COVID-19 & Access to Hydroxychloroquine At present the trials are ongoing and there isn’t sufficient evidence to conclude whether it will be effective. Science Magazine stated that the available evidence that chloroquine and hydroxychloroquine work against COVID-19 was ‘thin’. The U.S. Society of Critical Care Medicine said “there is insufficient evidence to issue a recommendation…

Alpha Project

International Lupus Community Reaches First-Ever Agreement on Barriers to Research, Drug Development, Care and Access Findings from a study published  in Lupus Science & Medicine™ provide an actionable framework to advance the lupus field, which has seen many failed clinical trials, variations in care and poor access to care worldwide. The study, “Global Consensus Building…